Document Detail


Alzheimer's disease.
MedLine Citation:
PMID:  21371747     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological and neuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease.
Authors:
Clive Ballard; Serge Gauthier; Anne Corbett; Carol Brayne; Dag Aarsland; Emma Jones
Related Documents :
23301777 - Wegener's granulomatosis: a review of clinical features and an update in diagnosis and ...
21155887 - Common variants in nod2 and il23r are not associated with inflammatory bowel disease in...
23746977 - Therapeutic translation of ipscs for treating neurological disease.
24314207 - The neurological disease ontology.
12396967 - Pathways to primary neurodegenerative disease.
21037477 - Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of igg4-related...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2011-03-01
Journal Detail:
Title:  Lancet     Volume:  377     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-22     Completed Date:  2011-04-20     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1019-31     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / diagnosis*,  epidemiology,  genetics,  therapy*
Amyloid beta-Peptides / metabolism
Biological Markers / blood,  cerebrospinal fluid
Brain / metabolism,  pathology
Delphi Technique
Diagnostic Imaging
Humans
Neurofibrillary Tangles / pathology
Neurologic Examination
Plaque, Amyloid / pathology
Prevalence
Risk Factors
tau Proteins / metabolism
Grant Support
ID/Acronym/Agency:
G9901400//Medical Research Council
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Biological Markers; 0/tau Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  BisGMA/TEGDMA ratio and filler content effects on shrinkage stress.
Next Document:  The inhibition of death receptor mediated apoptosis through lysosome stabilization following interna...